We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 23.50 | 1.38% | 1,728.50 | 1,727.50 | 1,728.50 | 1,729.50 | 1,695.50 | 1,705.00 | 6,275,082 | 16:35:24 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.44 | 71.14B |
From May 2019 to May 2024
By Josh Beckerman
Liquidia Technologies Inc. (LQDA), which reached a broad, multiyear collaboration with GlaxoSmithKline (GSK) in 2012, has amended the agreement for development of products using Liquidia's PRINT technology.
The amended agreement gives Liquidia the right to develop and commercialize three additional PRINT-based therapeutics delivered via inhalation. Additionally, Liquidia can acquire rights to pursue additional PRINT-based programs, subject to GlaxoSmithKline approval.
Liquidia's lead product candidate is LIQ861, a dry powder formulation of treprostinil that is being evaluated for the treatment of pulmonary arterial hypertension. The company said Wednesday that submitting an LIQ861 New Drug Application is its top priority for 2019, but "we also see clear opportunities to further expand the Liquidia pipeline of respiratory products."
Liquidia's initial public offering was in July 2018.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 26, 2019 19:13 ET (23:13 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
